HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

DNA topoisomerase II alpha

Subscribe to New Research on DNA topoisomerase II alpha

an isoform of DNA topoisomerases, type II, eukaryotic; a prognostic marker for certain cancers; RefSeq NM_022183 (rat), NM_011623 (mouse), NM_001067 (human)

Also Known As:

KiS1 antigen, human; TII-alpha protein, human; TOP2 protein, human; TOP2A protein; TOP2A protein, human; Top-2 protein, mouse; Top2a protein, mouse; Top2a protein, rat; antigen KiS1, human; proliferation-association antigen KiS1, human; topoisomerase (DNA) 2 alpha, rat; topoisomerase (DNA) II alpha 170kDa protein, human; topoisomerase (DNA) II alpha, mouse; topoisomerase II alpha; topoisomerase II alpha protein, human

Networked: 263 relevant articles (7 outcomes, 40 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Di Leo, Angelo: 6 articles (10/2013 - 08/2003)
2.	Di Leo, A: 5 articles (12/2013 - 05/2001)
3.	Larsimont, D: 5 articles (12/2013 - 05/2001)
4.	Sehested, Maxwell: 5 articles (02/2010 - 06/2002)
5.	Cardoso, F: 4 articles (12/2013 - 05/2001)
6.	Durbecq, V: 4 articles (12/2013 - 01/2004)
7.	Larsimont, Denis: 4 articles (10/2013 - 10/2004)
8.	Koren, Rumelia: 4 articles (12/2008 - 08/2004)
9.	Paesmans, M: 4 articles (08/2004 - 05/2001)
10.	Jensen, Peter B: 4 articles (06/2004 - 06/2002)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2005 - "The aim of our study was to evaluate the proliferative MIB-1 and topoisomerase II-alpha markers in both oncocytic and non-oncocytic epithelial thyroid tumors. " 06/01/2015 - "Our results suggest that in these tumors, selected marker staining seems to correlate with tumor differentiation; that is, well-differentiated tumors as a group stained with EMA and AR, and palisaded areas demonstrated consistent p53, topoisomerase II alpha and p27(kip1) staining. " 06/01/2015 - "Most of the tumors with well-differentiated palisaded areas demonstrated positive staining for topoisomerase II alpha, p27(kip1), and p53, with positive staining in tumoral basaloid areas (22/30). " 03/01/2014 - "Using positional proteomics in human tumor cells, we identified the nuclear enzyme topoisomerase II alpha (topoIIα) as a physiological substrate of GrM. " 01/01/2014 - "The surexpression of topoisomerase II alpha was associated within increased tumor stage. "
2.	Breast Neoplasms (Breast Cancer) 07/01/2010 - "The objective of this study was to develop a new real time PCR-based method for quantitative detection of topoisomerase II alpha (TOP2A) aberrations and to evaluate its clinical utility in breast cancer. " 06/01/2010 - "This study applied TMA in order to analyse the topoisomerase II alpha status in breast cancer and to elucidate its relationship in breast cancer biology. " 04/01/2004 - "In this study, we examined whether TOP2A gene amplification is an appropriate marker for identifying breast tumors expressing high levels of topoisomerase II alpha. " 06/01/2010 - "Topoisomerase II alpha expression failed to demonstrate prognostic value in patients with breast cancer." 06/01/2010 - "Archived tissue specimens from 94 patients with primary invasive breast cancer were selected and the topoisomerase II alpha expression was analysed by TMA. "
3.	Glioblastoma (Glioblastoma Multiforme) 05/01/2003 - "MIB-1 and DNA topoisomerase II alpha could be helpful for predicting long-term survival of patients with glioblastoma." 05/01/2003 - "Our study showed that both MIB-1 and topoisomerase II alpha could help predict long-term survival of patients with glioblastomas. " 06/19/2012 - "Quantitative analysis of topoisomerase II alpha and evaluation of its effects on cell proliferation and apoptosis in glioblastoma cancer stem cells." 05/01/2003 - "We studied the MIB-1 labeling index (LI) and DNA topoisomerase II alpha LI of glioblastomas from 34 patients who lived for more than 2 years after diagnosis and of glioblastomas from 34 age- and sex-matched control patients who died within 2 years of diagnosis. " 12/01/2000 - "Glial tumor cells in all glioblastomas showed constant up-regulation of LRP, MRP, and topoisomerase II alpha. "
4.	Colonic Neoplasms (Colon Cancer) 04/01/1999 - "To begin to correlate biologic response to Topo I drugs with the molecular characteristics of the neoplasm, we studied Topo I and DNA topoisomerase II-alpha (Topo II-alpha) expression in 29 cases of colon cancer. " 08/23/1996 - "Effect of acute and chronic intermittent hypoxia on DNA topoisomerase II alpha expression and mitomycin C-induced DNA damage and cytotoxicity in human colon cancer cells." 12/10/1999 - "We also found that a transient co-transfection with a DNA topoisomerase II alpha promoter-luciferase plasmid and an antisense YB-1 expression construct resulted in a significant reduction of the promoter activity in KM12C human colon cancer cells. "
5.	Wounds and Injuries (Trauma) 02/28/2010 - "Using the model of extravasation in a dexrazoxane-resistant transgenic mouse with a heterozygous mutation in the topoisomerase II alpha gene (Top2a(Y165S/+)), we found that dexrazoxane provided a protection against anthracycline-induced skin wounds that was indistinguishable from that found in wildtype mice. "

Related Drugs and Biologics

1.	Type II DNA Topoisomerases (Topoisomerase II)
2.	Razoxane (Dexrazoxane)
3.	Messenger RNA (mRNA)
4.	Anthracyclines
5.	Carbon Monoxide
6.	A-Form DNA (A-DNA)
7.	Luciferases
8.	trioctyl phosphine oxide (TOPO)
9.	Doxorubicin (Adriamycin)
10.	Mitoxantrone (Novantrone)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Adjuvant Chemotherapy
3.	Radiotherapy
4.	Combined Modality Therapy
5.	Neoadjuvant Therapy